and not used in the case of secondary lesions involving the leptomeningeal and pachymeningeal (dural) compartments; dural metastases can be further divided into epidural and subdural lesions.
On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell ...
REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and ...
Zacks Investment Research on MSN12d
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead DrugShares of Plus Therapeutics, Inc. PSTV were up a staggering 170.1% on March 20 after the company announced that the FDA has ...
Plus Therapeutics shares are trading higher by 183% during Thursday's session. The company announced that the FDA accepted ...
Small-Cap Firms Dominate Thursday’s Gains. In this article, we are going to take a look at where Plus Therapeutics Inc.
The recent $15 million financing accelerates development of REYOBIQ™ and launch of CNSide™HOUSTON, March 27, 2025 (GLOBE ...
Seven-year follow-up data of a multicenter, randomized phase 2 study evaluating the treatment of melanoma brain metastases shows ipilimumab plus nivolumab is an effective long-term care option. First ...
REYOBIQ™ (rhenium Re 186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback